Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors.

Chu J, Zhang W, Cencic R, Devine WG, Beglov D, Henkel T, Brown LE, Vajda S, Porco JA Jr, Pelletier J.

Cell Chem Biol. 2019 Nov 21;26(11):1586-1593.e3. doi: 10.1016/j.chembiol.2019.08.008. Epub 2019 Sep 10.

PMID:
31519508
2.

eIF4A Inhibitors Suppress Cell-Cycle Feedback Response and Acquired Resistance to CDK4/6 Inhibition in Cancer.

Kong T, Xue Y, Cencic R, Zhu X, Monast A, Fu Z, Pilon V, Sangwan V, Guiot MC, Foulkes WD, Porco JA Jr, Park M, Pelletier J, Huang S.

Mol Cancer Ther. 2019 Nov;18(11):2158-2170. doi: 10.1158/1535-7163.MCT-19-0162. Epub 2019 Aug 8.

PMID:
31395685
3.

Tracing MYC Expression for Small Molecule Discovery.

Steinberger J, Robert F, Hallé M, Williams DE, Cencic R, Sawhney N, Pelletier D, Williams P, Igarashi Y, Porco JA Jr, Rodriguez AD, Kopp B, Bachmann B, Andersen RJ, Pelletier J.

Cell Chem Biol. 2019 May 16;26(5):699-710.e6. doi: 10.1016/j.chembiol.2019.02.007. Epub 2019 Mar 14.

PMID:
30880156
4.

Oxo-aglaiastatin-Mediated Inhibition of Translation Initiation.

Itoua Maïga R, Cencic R, Chu J, Waller DD, Brown LE, Devine WG, Zhang W, Sebag M, Porco JA Jr, Pelletier J.

Sci Rep. 2019 Feb 4;9(1):1265. doi: 10.1038/s41598-018-37666-5.

5.

CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.

Xue Y, Meehan B, Macdonald E, Venneti S, Wang XQD, Witkowski L, Jelinic P, Kong T, Martinez D, Morin G, Firlit M, Abedini A, Johnson RM, Cencic R, Patibandla J, Chen H, Papadakis AI, Auguste A, de Rink I, Kerkhoven RM, Bertos N, Gotlieb WH, Clarke BA, Leary A, Witcher M, Guiot MC, Pelletier J, Dostie J, Park M, Judkins AR, Hass R, Levine DA, Rak J, Vanderhyden B, Foulkes WD, Huang S.

Nat Commun. 2019 Feb 4;10(1):558. doi: 10.1038/s41467-018-06958-9.

6.

A cautionary note on the use of cap analogue affinity resins.

Cencic R, Pelletier J.

Anal Biochem. 2018 Nov 1;560:24-29. doi: 10.1016/j.ab.2018.09.001. Epub 2018 Sep 4.

PMID:
30193929
7.

Rocaglates as dual-targeting agents for experimental cerebral malaria.

Langlais D, Cencic R, Moradin N, Kennedy JM, Ayi K, Brown LE, Crandall I, Tarry MJ, Schmeing M, Kain KC, Porco JA Jr, Pelletier J, Gros P.

Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):E2366-E2375. doi: 10.1073/pnas.1713000115. Epub 2018 Feb 20.

8.

Synthesis facilitates an understanding of the structural basis for translation inhibition by the lissoclimides.

Könst ZA, Szklarski AR, Pellegrino S, Michalak SE, Meyer M, Zanette C, Cencic R, Nam S, Voora VK, Horne DA, Pelletier J, Mobley DL, Yusupova G, Yusupov M, Vanderwal CD.

Nat Chem. 2017 Nov;9(11):1140-1149. doi: 10.1038/nchem.2800. Epub 2017 Jul 3.

9.

Huwe1 Regulates the Establishment and Maintenance of Spermatogonia by Suppressing DNA Damage Response.

Fok KL, Bose R, Sheng K, Chang CW, Katz-Egorov M, Culty M, Su S, Yang M, Ruan YC, Chan HC, Iavarone A, Lasorella A, Cencic R, Pelletier J, Nagano M, Xu W, Wing SS.

Endocrinology. 2017 Nov 1;158(11):4000-4016. doi: 10.1210/en.2017-00396.

PMID:
28938460
10.

Abstracts of the 52nd Workshop for Pediatric Research : Frankfurt, Germany. 27-28 October 2016.

van den Bruck R, Weil PP, Ziegenhals T, Schreiner P, Juranek S, Gödde D, Vogel S, Schuster F, Orth V, Dörner J, Pembaur D, Röper M, Störkel S, Zirngibl H, Wirth S, Jenke ACW, Postberg J, Boy N, Heringer J, Haege G, Glahn EM, Hoffmann GF, Garbade SF, Burgard P, Kölker S, Chao CM, Yahya F, Moiseenko A, Shrestha A, Ahmadvand N, Quantius J, Wilhelm J, El-Agha E, Zimmer KP, Bellusci S, Staufner C, Kölker S, Prokisch H, Hoffmann GF, Seeliger S, Müller M, Hippe A, Steinkraus H, Wauer R, Lachmann B, Hofmann SR, Hedrich CM, Zierk J, Arzideh F, Haeckel R, Rascher W, Rauh M, Metzler M, Thieme S, Bandoła J, Richter C, Ryser M, Jamal A, Ashton MP, von Bonin M, Kuhn M, Hedrich CM, Bonifacio E, Berner R, Brenner S, Hammersen J, Has C, Naumann-Bartsch N, Stachel D, Kiritsi D, Söder S, Tardieu M, Metzler M, Bruckner-Tuderman L, Schneider H, Bohne F, Langer D, Cencic R, Eggermann T, Zechner U, Pelletier J, Zepp F, Enklaar T, Prawitt D, Pech M, Weckmann M, Heinsen FA, Franke A, Happle C, Dittrich AM, Hansen G, Fuchs O, von Mutius E, Oliver BG, Kopp MV, Paret C, Russo A, Theruvath J, Keller B, El Malki K, Lehmann N, Wingerter A, Neu MA, Aslihan GA, Wagner W, Sommer C, Pietsch T, Seidmann L, Faber J, Schreiner F, Ackermann M, Michalik M, Rother E, Bilkei-Gorzo A, Racz I, Bindila L, Lutz B, Dötsch J, Zimmer A, Woelfle J, Fischer HS, Ullrich TL, Bührer C, Czernik C, Schmalisch G, Stein R, Hofmann SR, Hagenbuchner J, Kiechl-Kohlendorfer U, Obexer P, Ausserlechner MJ, Loges NT, Frommer AT, Wallmeier J, Omran H, Öner-Sieben S, Gimpfl M, Rozman J, Irmler M, Beckers J, De Angelis MH, Roscher A, Wolf E, Ensenauer R, Nemes K, Frühwald M, Hasselblatt M, Siebert R, Kordes U, Kool M, Wang H, Hardy H, Refai O, Barwick KES, Zimmerman HH, Weis J, Baple EL, Crosby AH, Cirak S, Hellmuth C, Uhl O, Standl M, Heinrich J, Thiering E, Koletzko B, Blümel L, Kerl K, Picard D, Frühwald MC, Liebau MC, Reifenberger G, Borkhardt A, Hasselblatt M, Remke M, Tews D, Wabitsch M, Fischer-Posovszky P, Westhoff MA, Nonnenmacher L, Langhans J, Schneele L, Trenkler N, Debatin KM.

Mol Cell Pediatr. 2017 May;4(Suppl 1):5. doi: 10.1186/s40348-017-0071-0. No abstract available.

11.

A New Natural Product Analog of Blasticidin S Reveals Cellular Uptake Facilitated by the NorA Multidrug Transporter.

Davison JR, Lohith KM, Wang X, Bobyk K, Mandadapu SR, Lee SL, Cencic R, Nelson J, Simpkins S, Frank KM, Pelletier J, Myers CL, Piotrowski J, Smith HE, Bewley CA.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02635-16. doi: 10.1128/AAC.02635-16. Print 2017 Jun.

12.

Structure of human IFIT1 with capped RNA reveals adaptable mRNA binding and mechanisms for sensing N1 and N2 ribose 2'-O methylations.

Abbas YM, Laudenbach BT, Martínez-Montero S, Cencic R, Habjan M, Pichlmair A, Damha MJ, Pelletier J, Nagar B.

Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2106-E2115. doi: 10.1073/pnas.1612444114. Epub 2017 Mar 1.

13.

A CRISPR/Cas9 Functional Screen Identifies Rare Tumor Suppressors.

Katigbak A, Cencic R, Robert F, Sénécha P, Scuoppo C, Pelletier J.

Sci Rep. 2016 Dec 16;6:38968. doi: 10.1038/srep38968.

14.

Synthesis of Aza-Rocaglates via ESIPT-Mediated (3+2) Photocycloaddition.

Wang W, Cencic R, Whitesell L, Pelletier J, Porco JA Jr.

Chemistry. 2016 Aug 16;22(34):12006-10. doi: 10.1002/chem.201602953. Epub 2016 Jul 15.

15.

Hippuristanol - A potent steroid inhibitor of eukaryotic initiation factor 4A.

Cencic R, Pelletier J.

Translation (Austin). 2016 Jan 4;4(1):e1137381. doi: 10.1080/21690731.2015.1137381. eCollection 2016 Jan-Jun. Review.

16.

CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A.

Chu J, Galicia-Vázquez G, Cencic R, Mills JR, Katigbak A, Porco JA Jr, Pelletier J.

Cell Rep. 2016 Jun 14;15(11):2340-7. doi: 10.1016/j.celrep.2016.05.005. Epub 2016 May 26.

17.

5,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells.

Henry S, Kidner R, Reisenauer MR, Magedov IV, Kiss R, Mathieu V, Lefranc F, Dasari R, Evidente A, Yu X, Ma X, Pertsemlidis A, Cencic R, Pelletier J, Cavazos DA, Brenner AJ, Aksenov AV, Rogelj S, Kornienko A, Frolova LV.

Eur J Med Chem. 2016 Sep 14;120:313-28. doi: 10.1016/j.ejmech.2016.05.004. Epub 2016 May 6.

18.

Haploinsufficiency of the ESCRT Component HD-PTP Predisposes to Cancer.

Manteghi S, Gingras MC, Kharitidi D, Galarneau L, Marques M, Yan M, Cencic R, Robert F, Paquet M, Witcher M, Pelletier J, Pause A.

Cell Rep. 2016 May 31;15(9):1893-900. doi: 10.1016/j.celrep.2016.04.076. Epub 2016 May 19.

19.

Kaiso mediates human ICR1 methylation maintenance and H19 transcriptional fine regulation.

Bohne F, Langer D, Martiné U, Eider CS, Cencic R, Begemann M, Elbracht M, Bülow L, Eggermann T, Zechner U, Pelletier J, Zabel BU, Enklaar T, Prawitt D.

Clin Epigenetics. 2016 May 4;8:47. doi: 10.1186/s13148-016-0215-4. eCollection 2016.

20.

Repression of p53-target gene Bbc3/PUMA by MYSM1 is essential for the survival of hematopoietic multipotent progenitors and contributes to stem cell maintenance.

Belle JI, Petrov JC, Langlais D, Robert F, Cencic R, Shen S, Pelletier J, Gros P, Nijnik A.

Cell Death Differ. 2016 May;23(5):759-75. doi: 10.1038/cdd.2015.140. Epub 2016 Jan 15.

21.

Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status.

Chu J, Cencic R, Wang W, Porco JA Jr, Pelletier J.

Mol Cancer Ther. 2016 Jan;15(1):136-41. doi: 10.1158/1535-7163.MCT-15-0409. Epub 2015 Nov 19.

22.

Establishment of a Primary Screening Assay for the DHX9 Helicase.

Cencic R, Senechal P, Pelletier J.

Comb Chem High Throughput Screen. 2015;18(9):855-61.

PMID:
26477352
23.

Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim.

Nguyen M, Cencic R, Ertel F, Bernier C, Pelletier J, Roulston A, Silvius JR, Shore GC.

BMC Cancer. 2015 Aug 1;15:568. doi: 10.1186/s12885-015-1582-5.

24.

Adapting CRISPR/Cas9 for functional genomics screens.

Malina A, Katigbak A, Cencic R, Maïga RI, Robert F, Miura H, Pelletier J.

Methods Enzymol. 2014;546:193-213. doi: 10.1016/B978-0-12-801185-0.00010-6.

PMID:
25398342
25.

Protospacer adjacent motif (PAM)-distal sequences engage CRISPR Cas9 DNA target cleavage.

Cencic R, Miura H, Malina A, Robert F, Ethier S, Schmeing TM, Dostie J, Pelletier J.

PLoS One. 2014 Oct 2;9(10):e109213. doi: 10.1371/journal.pone.0109213. eCollection 2014.

26.

Foot-and-mouth disease virus leader proteinase: structural insights into the mechanism of intermolecular cleavage.

Steinberger J, Grishkovskaya I, Cencic R, Juliano L, Juliano MA, Skern T.

Virology. 2014 Nov;468-470:397-408. doi: 10.1016/j.virol.2014.08.023. Epub 2014 Sep 19.

27.

Synthesis of the antiproliferative agent hippuristanol and its analogues from hydrocortisone via Hg(II)-catalyzed spiroketalization: structure-activity relationship.

Somaiah R, Ravindar K, Cencic R, Pelletier J, Deslongchamps P.

J Med Chem. 2014 Mar 27;57(6):2511-23. doi: 10.1021/jm401799j. Epub 2014 Mar 11.

PMID:
24588834
28.

Internal translation initiation from HIV-1 transcripts is conferred by a common RNA structure.

Plank TD, Whitehurst JT, Cencic R, Pelletier J, Kieft JS.

Translation (Austin). 2014 Jan 29;2(1):e27694. doi: 10.4161/trla.27694. eCollection 2014.

29.

Repurposing CRISPR/Cas9 for in situ functional assays.

Malina A, Mills JR, Cencic R, Yan Y, Fraser J, Schippers LM, Paquet M, Dostie J, Pelletier J.

Genes Dev. 2013 Dec 1;27(23):2602-14. doi: 10.1101/gad.227132.113.

30.

Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A.

Cencic R, Robert F, Galicia-Vázquez G, Malina A, Ravindar K, Somaiah R, Pierre P, Tanaka J, Deslongchamps P, Pelletier J.

Blood Cancer J. 2013 Jul 19;3:e128. doi: 10.1038/bcj.2013.25.

31.

Throwing a monkey wrench in the motor: targeting DExH/D box proteins with small molecule inhibitors.

Cencic R, Pelletier J.

Biochim Biophys Acta. 2013 Aug;1829(8):894-903. doi: 10.1016/j.bbagrm.2013.01.008. Epub 2013 Feb 4. Review.

PMID:
23385390
32.

Inhibitors of translation targeting eukaryotic translation initiation factor 4A.

Cencic R, Galicia-Vázquez G, Pelletier J.

Methods Enzymol. 2012;511:437-61. doi: 10.1016/B978-0-12-396546-2.00020-6.

PMID:
22713332
33.

A cellular response linking eIF4AI activity to eIF4AII transcription.

Galicia-Vázquez G, Cencic R, Robert F, Agenor AQ, Pelletier J.

RNA. 2012 Jul;18(7):1373-84. doi: 10.1261/rna.033209.112. Epub 2012 May 15.

34.

Targeting protein synthesis in a Myc/mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival.

Robert F, Mills JR, Agenor A, Wang D, DiMarco S, Cencic R, Tremblay ML, Gallouzi IE, Hekimi S, Wing SS, Pelletier J.

Cancer Res. 2012 Feb 1;72(3):747-56. doi: 10.1158/0008-5472.CAN-11-2739. Epub 2011 Dec 12.

35.

Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.

Rodrigo CM, Cencic R, Roche SP, Pelletier J, Porco JA.

J Med Chem. 2012 Jan 12;55(1):558-62. doi: 10.1021/jm201263k. Epub 2011 Dec 19.

36.

Structural conservation of druggable hot spots in protein-protein interfaces.

Kozakov D, Hall DR, Chuang GY, Cencic R, Brenke R, Grove LE, Beglov D, Pelletier J, Whitty A, Vajda S.

Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13528-33. doi: 10.1073/pnas.1101835108. Epub 2011 Aug 1.

37.

Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication.

Cencic R, Desforges M, Hall DR, Kozakov D, Du Y, Min J, Dingledine R, Fu H, Vajda S, Talbot PJ, Pelletier J.

J Virol. 2011 Jul;85(13):6381-9. doi: 10.1128/JVI.00078-11. Epub 2011 Apr 20.

38.

Targeting translation dependence in cancer.

Malina A, Cencic R, Pelletier J.

Oncotarget. 2011 Jan-Feb;2(1-2):76-88. Review.

39.

Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F.

Cencic R, Hall DR, Robert F, Du Y, Min J, Li L, Qui M, Lewis I, Kurtkaya S, Dingledine R, Fu H, Kozakov D, Vajda S, Pelletier J.

Proc Natl Acad Sci U S A. 2011 Jan 18;108(3):1046-51. doi: 10.1073/pnas.1011477108. Epub 2010 Dec 29. Erratum in: Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6689.

40.

Biomimetic photocycloaddition of 3-hydroxyflavones: synthesis and evaluation of rocaglate derivatives as inhibitors of eukaryotic translation.

Roche SP, Cencic R, Pelletier J, Porco JA Jr.

Angew Chem Int Ed Engl. 2010 Sep 3;49(37):6533-8. doi: 10.1002/anie.201003212. No abstract available.

41.

Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells.

Cencic R, Carrier M, Trnkus A, Porco JA Jr, Minden M, Pelletier J.

Leuk Res. 2010 Apr;34(4):535-41. doi: 10.1016/j.leukres.2009.07.043. Epub 2009 Sep 1.

42.

Blocking UV-induced eIF2alpha phosphorylation with small molecule inhibitors of GCN2.

Robert F, Williams C, Yan Y, Donohue E, Cencic R, Burley SK, Pelletier J.

Chem Biol Drug Des. 2009 Jul;74(1):57-67. doi: 10.1111/j.1747-0285.2009.00827.x.

PMID:
19519745
43.

Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol.

Cencic R, Carrier M, Galicia-Vázquez G, Bordeleau ME, Sukarieh R, Bourdeau A, Brem B, Teodoro JG, Greger H, Tremblay ML, Porco JA Jr, Pelletier J.

PLoS One. 2009;4(4):e5223. doi: 10.1371/journal.pone.0005223. Epub 2009 Apr 29.

44.

c-Myc and eIF4F are components of a feedforward loop that links transcription and translation.

Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J.

Cancer Res. 2008 Jul 1;68(13):5326-34. doi: 10.1158/0008-5472.CAN-07-5876. Erratum in: Cancer Res. 2008 Sep 1;68(17):7246.

45.

Residue L143 of the foot-and-mouth disease virus leader proteinase is a determinant of cleavage specificity.

Mayer C, Neubauer D, Nchinda AT, Cencic R, Trompf K, Skern T.

J Virol. 2008 May;82(9):4656-9. doi: 10.1128/JVI.02077-07. Epub 2008 Feb 27.

46.

Selective pharmacological targeting of a DEAD box RNA helicase.

Lindqvist L, Oberer M, Reibarkh M, Cencic R, Bordeleau ME, Vogt E, Marintchev A, Tanaka J, Fagotto F, Altmann M, Wagner G, Pelletier J.

PLoS One. 2008 Feb 13;3(2):e1583. doi: 10.1371/journal.pone.0001583.

47.

Identifying small molecule inhibitors of eukaryotic translation initiation.

Cencic R, Robert F, Pelletier J.

Methods Enzymol. 2007;431:269-302. Review.

PMID:
17923239
48.

Investigating the substrate specificity and oligomerisation of the leader protease of foot and mouth disease virus using NMR.

Cencic R, Mayer C, Juliano MA, Juliano L, Konrat R, Kontaxis G, Skern T.

J Mol Biol. 2007 Nov 2;373(4):1071-87. Epub 2007 Sep 1.

PMID:
17897674
49.

Enantioselective synthesis of the complex rocaglate (-)-silvestrol.

Gerard B, Cencic R, Pelletier J, Porco JA Jr.

Angew Chem Int Ed Engl. 2007;46(41):7831-4. No abstract available.

PMID:
17806093
50.

Homogenous time resolved fluorescence assay to identify modulators of cap-dependent translation initiation.

Cencic R, Yan Y, Pelletier J.

Comb Chem High Throughput Screen. 2007 Mar;10(3):181-8.

PMID:
17346117

Supplemental Content

Loading ...
Support Center